BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Dolutegravir

An HIV integrase inhibitor that is used in the treatment of HIV INFECTIONS in combination with other ANTI-HIV AGENTS.

298+ PubMed studies analyzed · 51 RCTs · Evidence Score: 53.3

Research Domains

Dolutegravir has been studied across 12 research domains including 🔥 Metabolic, 😴 Sleep, 🧠 Focus & Attention, 🫁 Liver & Detox, 🫘 Kidney. The primary research focus is 🔥 Metabolic with 4% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Dolutegravir, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

vesamicol
2 shared targets
siramesine
2 shared targets
ditolylguanidine
2 shared targets
11csa4503
2 shared targets
5
2 shared targets
amantadine
2 shared targets
carbetapentane
2 shared targets
propranolol
2 shared targets
azaperone
2 shared targets
Tolterodine
2 shared targets
Loading evidence profile...

This evidence profile for Dolutegravir is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.